<DOC>
	<DOCNO>NCT02998996</DOCNO>
	<brief_summary>The main purpose study evaluate safety tolerability Immunose™ FLU base Endocine™ quadrivalent influenza antigen .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability Immune Response Following Vaccination With Immunose™ FLU</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Signed informed consent prior study related procedure . Male female 1839 year age ( inclusive ) screen Subjects Investigator believe comply requirement protocol . BMI : 18.0 30.0 kg/m2 ( inclusive ) . Judged Investigator serious illness base medical history , physical examination , ECG , vital sign blood urine assessment screen . From sign inform consent 2 month last vaccination ( Visit 3 group 1 4 Visit 2 group 5 6 ) female subject use contraceptive method failure rate &lt; 1 % prevent pregnancy ( combine [ oestrogen progestogen contain ] hormonal contraception associate inhibition ovulation [ oral , intravaginal , transdermal ] , progestogen hormonal contraception associate inhibition ovulation [ oral , injectable , implantable ] , intrauterine device [ IUD ] , intrauterine hormonereleasing system [ IUS ] , bilateral tubal occlusion , sexual abstinence ) . Any male partner willing use condom vasectomize . Diagnosis laboratoryconfirmed influenza 2015/2016 season . Use investigational drug product within 3 month screen plan use study period , include safety followup . Administration influenza vaccine 6 month screen . Previously receive another vaccine within 28 day administration study vaccine , schedule receive another vaccine study period , exclude safety followup . Any contraindication intramuscular administration influenza vaccine AdimFluS accord prescribe information . Any contraindication administration influenza vaccine Fluenz Tetra accord summary product characteristic ( SmPC ) . History anaphylactic reaction and/or serious allergic reaction follow vaccination , proven hypersensitivity component study vaccine ( e.g. , eggs egg product well ovalbumin , chicken protein , chicken feather , influenza viral protein , kanamycin , gentamycin neomycin sulphate ) . Diagnosis asthma poor disease control assess Investigator . Potent immunosuppressive therapy include cytostatics , antibody , drug act immunophilins , interferon drug use prevent rejection organ transplant , within 6 month screen . Use parenteral oral corticosteroid within 30 day prior screen . Inhaled steroid allow . Any confirmed suspected immunosuppressive immunodeficient condition , base medical history physical examination . Any progressive severe neurologic disorder , seizure disorder GuillainBarré syndrome . History GuillainBarré syndrome within 6 week receipt prior inactivate influenza virus vaccine . Received blood , blood product and/or plasma derivative administration immunoglobulin preparation within three month prior Visit 2 , plan study . Participation blood donation within 3 month plasma donation within 1 month prior Visit 2 . History substance alcohol abuse within past 2 year . History illness/condition , opinion Investigator , might interfere result study pose additional risk subject due participation study . Any positive result screen serum hepatitis B surface antigen , hepatitis C antibody HIV . Pregnant lactate female intent become pregnant clinic phase ( include Visit 4 group 1 4 Visit 3 group 5 6 ) 2 month last vaccination . History Bell 's palsy . Ongoing regular use intranasal spray include corticosteroid decongestant . Ongoing cough , sinusitis , allergic rhinitis , nasal polyp obstruction , include septum deviation significant enough prevent bilateral administration study vaccine . Known bleed diathesis , condition may associate prolonged bleeding time . Subjects prone nosebleed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>